GSK has received approval from Japan's MHLW for its application to extend the indication of its RSV vaccine, Arexvy.

Learn about this vaccine that protects against a common seasonal virus that can sometimes cause severe disease, with info on ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.BMDkfsfZ.js ...

Arexvy, the first RSV vaccine approved in the country for this age group, is currently authorised in the US and a further 35 countries. The vaccine's active ingredient is a recombinant RSV ...

After six straight quarters in which Eli Lilly or Novo Nordisk achieved the highest year-over-year revenue growth among the ...

GlaxoSmithKline (GSK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Justin Smith from ...

Sales of GSK's respiratory syncytial virus (RSV) vaccine Arexvy slumped 72% in the third quarter of this year, as narrower recommendations on its use in the US started to have an effect.

The FDA has approved GSK’s Arexvy shot for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older, shortly after it was recommended for approval ...